246 related articles for article (PubMed ID: 29590674)
1. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
[TBL] [Abstract][Full Text] [Related]
2. Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of
Happel C; Kranert WT; Gröner D; Baumgarten J; Halstenberg J; Bockisch B; Sabet A; Grünwald F
Endocrine; 2021 Jul; 73(1):125-130. PubMed ID: 33439464
[TBL] [Abstract][Full Text] [Related]
3. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine therapy of Graves' hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy?
Dederichs B; Dietlein M; Jenniches-Kloth B; Schmidt M; Theissen P; Moka D; Schicha H
Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):366-70. PubMed ID: 16915539
[TBL] [Abstract][Full Text] [Related]
5. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
6. The influence of thionamides on intra-thyroidal uptake of
Happel C; Bockisch B; Leonhäuser B; Sabet A; Grünwald F; Groener D
Sci Rep; 2023 Dec; 13(1):21190. PubMed ID: 38040820
[TBL] [Abstract][Full Text] [Related]
7. Strategies of radioiodine therapy for Graves' disease.
Lind P
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S453-7. PubMed ID: 12192545
[TBL] [Abstract][Full Text] [Related]
8. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
9. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease.
Hautzel H; Pisar E; Yazdan-Doust N; Schott M; Beu M; Müller HW
J Nucl Med; 2010 Dec; 51(12):1917-22. PubMed ID: 21078788
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for the outcome of radioiodine therapy in patients with benign thyroid diseases.
Wedel F; Exarchopoulos T; Brenner W
Nuklearmedizin; 2024 Apr; 63(2):69-75. PubMed ID: 38190997
[TBL] [Abstract][Full Text] [Related]
11.
Zhao L; Zhang W; Xin Y; Wen Q; Bail L; Guan F; Bin J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(6):349-353. PubMed ID: 30413358
[TBL] [Abstract][Full Text] [Related]
12. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease.
Zantut-Wittmann DE; Ramos CD; Santos AO; Lima MM; Panzan AD; Facuri FV; Etchebehere EC; Lima MC; Tambascia MA; Camargo EE
Nucl Med Commun; 2005 Nov; 26(11):957-63. PubMed ID: 16208172
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy and Graves' disease - Myths and reality.
Plazinska MT; Sawicka-Gutaj N; Czarnywojtek A; Wolinski K; Kobylecka M; Karlińska M; Prasek K; Zgorzalewicz-Stachowiak M; Borowska M; Gut P; Ruchala M; Krolicki L
PLoS One; 2020; 15(1):e0226495. PubMed ID: 31929534
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease.
Jensen BE; Bonnema SJ; Hegedüs L
Eur J Endocrinol; 2005 Jul; 153(1):15-21. PubMed ID: 15994741
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for the outcomes of Graves' disease patients with radioactive iodine (131I) treatment.
Xing YZ; Zhang K; Jin G
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31840740
[TBL] [Abstract][Full Text] [Related]
16. [Predictors of the efficacy of radioiodine therapy of Graves' disease in children and adolescents].
Rumyantsev PO; Saenko VA; Dzeytova DS; Trukhin AA; Sheremeta MS; Slashchuk KY; Degtyarev MV; Serzhenko SS; Yasuchenia VS; Zakharova SM; Sirota YI
Probl Endokrinol (Mosk); 2020 Oct; 66(4):68-76. PubMed ID: 33351361
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
18. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
Urbannek V; Voth E; Moka D; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
[TBL] [Abstract][Full Text] [Related]
19. Do glucocorticoids affect outcome in Graves' disease following radioiodine therapy?
Salvatore D; Fenzi G
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):194-5. PubMed ID: 16932282
[No Abstract] [Full Text] [Related]
20. Graves' disease and radioiodine therapy. Is success of ablation dependent on the choice of thyreostatic medication?
Kobe C; Weber I; Eschner W; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nuklearmedizin; 2008; 47(4):153-6. PubMed ID: 18690374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
